or
Nature Reviews Drug Discovery 25, 12-13 (2026)
doi: https://doi.org/10.1038/d41573-025-00198-5
Acknowledgements
We thank the many people at the different agencies supporting this pilot. Specifically, we thank the coordinators from the Scientific Advice Working Party (SAWP) who were involved in this project and colleagues from EMA’s scientific advice, real-world evidence, methodology, academia and regulatory affairs offices. We thank R. Ruano, J. Ruiz, T. Arroyo for their contributions to AEMPS advice during the pilot, T. Girard and I. Gravanis for their support to perform this pilot and their review of this manuscript, and G. Borg for his work on data collection and developing the figures. We thank F. Pignatti and J. Jansen for their comments and support in drafting this manuscript.
Disclaimer
The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.
The authors declare no competing interests.
